2022 | Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice | Le, Xiuning; Sakai, Hiroshi; Felip, Enriqueta; Veillon, Remi; Garassino, Marina Chiara; Raskin, Jo; Cortot, Alexis B; Viteri, Santiago; Mazieres, Julien; Smit, Egbert F; Thomas, Michael; Iams, Wade T; Cho, Byoung Chul; Kim, Hye Ryun; CHIH-HSIN YANG ; Chen, Yuh-Min; Patel, Jyoti D; Bestvina, Christine M; Park, Keunchil; Griesinger, Frank; Johnson, Melissa; Gottfried, Maya; Britschgi, Christian; Heymach, John; Sikoglu, Elif; Berghoff, Karin; Schumacher, Karl-Maria; Bruns, Rolf; Otto, Gordon; Paik, Paul K | Clinical cancer research : an official journal of the American Association for Cancer Research | 48 | 39 | |
2015 | TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC | Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony | J. Thorac. Oncol. | | | |